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Long-term outcomes of catheter directed
thrombolysis for lower extremity deep venous
thrombosis without prophylactic inferior vena cava
filter placement
Clinton D. Protack, BS, Andrew M. Bakken, MD, Nikhil Patel, MD, Wael E. Saad, MD,
David L. Waldman, MD, PhD, and Mark G. Davies, MD, PhD, Rochester, NY
Background: While the predominant treatment of lower extremity deep venous thrombosis (DVT) remains systemic
anticoagulation, there is a growing consensus that more aggressive percutaneous catheter directed thrombolysis (CDT)
carries both short-term and long-term benefits. There remains controversy as to whether an inferior vena cava (IVC) filter
is always required during CDT.
Objective: To define the short- and long-term outcomes of CDT with and without prophylactic IVC filter placement for
lower extremity DVT.
Methods: A database of patients treated by CDT from 1996 to 2006 was compiled. Results were standardized to current
Society for Vascular Surgery criteria. Average follow-up was 2.1 years, range of 1-8 years. Kaplan-Meier survival analyses
were performed to assess time-dependent outcomes. Factor analyses were performed using a Cox proportional hazard
model for time dependent variables. Data are presented as mean  SD where appropriate.
Results: Sixty-nine patients (39% male, average age 48  17 years) underwent CDT: (27 received pharmacological
thrombolysis, 12 received mechanical thrombolysis, and 30 received mechanical and pharmacological thrombolysis).
Fourteen patients (20%) had IVC filter placement prior to or during CDT. Twenty-one had a hypercoagulable state.
Technical success with grade III lysis of clot burden was achieved in 63%. Fifty-one patients required an adjuvant stent.
Overall, 90-day all-cause mortality was 4% and peri-procedural morbidity was 4%. No patients developed a pulmonary
embolus (PE) during therapy. By Kaplan-Meier analysis 83%, 83%, and 75% of patients were free of recurrent DVT at 1,
2, and 3 years, respectively. Hypercoagulability was associated with DVT recurrence by Cox proportional hazards
analysis. No analyzed factor was predictive of PE.
Conclusion: Catheter directed thrombolysis without universal prophylactic IVC filter placement is safe and effective in
treating acute DVT. Pulmonary embolization did not occur during CDT. Selective rather than routine IVC filter
placement is a safe and appropriate approach. (J Vasc Surg 2007;45:992-7.)The incidence of deep venous thromboembolism
(DVT) is quite common and can lead to pulmonary embo-
lism (PE) in the short term and chronic venous insufficiency
in the long term.1,2 The conventional treatment of acute
DVT is systemic anticoagulation with either unfractionated
or low-molecular weight heparin.3 While systemic antico-
agulation is instrumental in preventing propagation and
PE, it fails to reduce or even eliminate the actual clot; that
is resolved by the patient’s own system. Reduction of clot
burden or complete clearance of the clot by either pharma-
cological or mechanical means is considered advantageous
to preserve valvular function and reduce the risk of chronic
venous insufficiencies. Endovascular management of DVTs
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992began in the early 1990s4 and reports have shown that it
can more effectively reduce clot burden5 and provide
greater quality of life vs anticoagulation alone.6 Addition-
ally, catheter-directed thrombolysis (CDT) has been shown
as safe and effective for Protein C & S deficient patients,7
and those with May-Thurner syndrome.8 A theoretical risk
of clot dissolution is iatrogenic induced PE and conven-
tional wisdomwould suggest that in a patient at high risk of
PE an inferior vena cava (IVC) filter should be placed.
However the frequency of PE after pharmacological or
mechanical thrombolysis remains low.
The aim of this report is to retrospectively examine our
experience over the last 10 years of CDT for lower extrem-
ity DVTs and to define the short- and long-term outcomes
of CDT with and without universal prophylactic IVC filter
placement.
METHODS
Study setting. This study was performed at an aca-
demic medical center in a metropolitan area of approxi-
mately 1 million persons and a surrounding overall catch-
ment are of approximately 5 million in Western New York
State. The University of Rochester Medical Center is a
tertiary referral center with a dedicated vascular service line.
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tients undergoing CDT for lower extremity DVT from
1996 to 2006 was maintained. Data utilization fell under
the category of secondary use of pre-existing data.
Methods. For each patient, demographics, symptoms,
existing comorbid conditions, and risk factors for DVT
were identified. Periprocedural parameters were obtained
from the record. Follow-up was by clinical assessment and
duplex ultrasound scans performed at 1, 6, and 12 months
after the intervention and every 12 months thereafter. The
procedure of CDT has been described previously.4 The
decision for IVC filter placement was provider specific.
After the procedure, patients were commenced on warfarin
and aspirin, and this was continued for 3 months. If the
patient had an inherited hypercoagulable state, then warfa-
rin and aspirin were continued for life. All patients were
recommended to use elastic compression stockings.
Definitions. Coronary artery disease was defined as a
history of angina pectoris, myocardial infarction, conges-
tive heart disease, or prior coronary artery revasculariza-
tions. Hypertension was defined as a systolic blood pressure
greater than 150mmHg or diastolic blood pressure greater
than 90 mm Hg on three occasions during a 6-month
period. A death within 30 days of the procedure was
considered procedure-related. A major complication was
defined as any event, regardless of how minimal, not rou-
tinely observed after endoluminal therapy that required
treatment with a therapeutic intervention or rehospitaliza-
tion within 30 days of the procedure.
Procedural success was determined as greater than 90%
clot burden removal. Clot burden for each vessel was
scored from zero to three, as previously described.9 A vessel
score of zero indicated a patent vessel. A vessel score of one
indicated a subsegmental, nonocclusive thrombus was
present. A vessel score of two indicated a subsegmental,
occlusive thrombus was present, and a vessel score of three
indicated an occlusive thrombus the entire length of the
vessel segment was present. Each vessel (vena cava, iliac,
common femoral, femoral, popliteal, and tibia-soleal) was
individually scored and then added together to generate
the clot burden for the entire limb. The post-CDT clot
burden score was calculated at the final conclusion of
treatment, which included stent deployment. The clot bur-
den reduction was calculated as the difference between pre-
and post-CDT limb scores, then divided by the pre-CDT
score, and then multiplied by 100%. grade I lysis was
defined as50% clot burden removal, grade II lysis as 50%
to 99% clot burden removal, and grade III lysis as 100% clot
burden removal.
Vessel stenting was indicated if non-TIMI III flow was
present at the conclusion of therapy.
Routine pre- and postoperative ventilation perfusion
(V/Q) scans or spiral computed tomography (CT) studies
were not performed unless there was clinical suspicion for a
PE. Thus, detection of postprocedural PE depended upon
the patient presenting with symptoms that raised clinical
suspicion of PE and resulted in a V/Q scan or spiral CT,
which demonstrated PE.The earliest date that any of the six lower extremity
vessels originally treated by CDT, demonstrated thrombo-
sis was defined as the re-thrombosis date. Freedom from
re-thrombosis was not based on each individual vessel, but
instead the patient as a whole.
Statistical analysis. All statistical analyses were per-
formed on an “intention to treat” basis. Measured values
are reported as percentages or means  1 standard devia-
tion. Survival, patency and neurological-free and major
adverse event rates are calculated using Kaplan-Meier anal-
ysis and reported using current SVS criteria. Standard errors
are reported in Kaplan-Meier analyses. The log rank test
was used to determine differences between life tables. Mul-
tivariate stepwise regression analysis was used to determine
the influence of preprocedural and periprocedural factors
on outcomes. The significance level P  .10 was used to
include or eliminate a covariate from the model. Covariates
were considered to be significantly associated with the
outcome if they were included in the final model and their
significance level was P  .05. Interactions between statis-
tically significant covariates were checked. Logistic regres-
sion models were used for outcomes that were measured
shortly after the procedure (complications, short term clin-
ical benefits). The dependence of each covariate on the
outcome was first checked separately using the 2 test.
Covariates with the significance level of P  .10 were
included in the multivariate stepwise analysis.
RESULTS
Patient Population. Sixty-nine patients underwent
CDT for lower extremity deep venous thrombolysis from
1996 to 2006. Twenty-seven (39%) were male. The mean
age was 48  17 years, with a median of 49 years and a
range of 15 to 84 years. Seven of the 41 female patients
(17%) were currently using oral contraceptive pills. Twenty
patients (29%) had a DVT in the past, while four (6%)
patients had a PE in the past (see Table I).
The 69 patients undergoing CDT presented with 197
thrombosed vessels. Twenty-one patients (30%) had clot
involving the vena cava. Fifty-five (80%) had involvement of
the iliac. Forty-seven (68%) and 40 (58%) patients had
involvement of the common femoral and femoral vessels,
respectively. Thirty (43%) and four (6%) of the patients had
involvement of the popliteal and tibial-soleal vessels.
The breakdown of patient comorbidities are as follows:
Table I. Patient characteristics
Age (mean  SD, years) 48  17
 80 years 1 (1%)
Gender (male) 27 (39%)
History of previous DVT 20 (29%)
History of previous PE 4 (6%)
Presents with pulmonary embolism 8 (12%)
Presents with phlegmasia cerulea dolens 11 (16%)
May-Thurner 11 (16%)
Current malignancy 9 (13%)7 with coronary artery disease (10%), 9 with diabetes mel-
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nicotine (41%). Regarding patients with an identifiable
hypercoagulable state the following were present in twenty-
one patients (30%): 2 protein C deficient, 6 protein S
deficient, 6 factor V Leiden heterozygote, 0 factor V Lei-
den homozygote, 0 G20210A prothrombin heterozygote,
1 G20210A prothrombin homozygote, 3 lupus anticoag-
ulant, and 9 (13%) had a concurrent malignancy. Three
patients (4%) previously had an IVC filter placed. Eight
patients (12%) presented with pulmonary embolism. Three
patients (4%) presented with bilateral DVTs. Eleven (16%)
were characterized as May-Thurner, and 11 (16%) pre-
sented with phlegmasia cerulea dolens.
Procedures. The breakdown of procedures performed
is as follows: 12 (17%) mechanical thrombolysis alone, 27
(40%) pharmacologic therapy alone, 30 (43%) pharmaco-
logic and pulse-spray therapy (see Table II). For those
receiving pharmacologic therapy, 16 (24%) continued for
24 hours, 32 (47%) for 48 hours, and 5 (7%) for 72 hours.
Of those receiving pharmacologic therapy, 33 (62%) re-
ceived tissue Plasminogen Activator (tPA), five (10%) re-
ceived retavase, and 15 (28%) received urokinase. While the
thrombolytic drug was being infused, 300 units/hr of
heparin was also administered. Seventeen (25%) did not
require a stent, 27 (40%) received one stent, 17 (25%)
received two stents, 5 (7%) received three stents, and 2 (3%)
received four stents. By 2 analysis, no difference existed
between the rate of vessel stenting between May-Thurner
and non-May-Thurner patients. IVC filters were placed in
11(16%) patients. With three patients with previous IVC
filter placement, a total of 14 (20%) patients had IVC filters
at the end of CDT therapy.
Complications were experienced during five proce-
dures: rupture of the common iliac vein, heme-pigment
induced acute tubular necrosis, post-CDT bacteremia,
transient hypotension, and transient bradycardia. The third
patient who developed bacteremia had acute myelogenous
leukemia and was neutropenic at the time of CDT.
Intraoperative pre-CDT and post-CDT clot burden is
described in Table III. The overall limb score decreased
from an average 8.1, pre-CDT, to an average 0.9, post-
CDT. The mean clot burden reduction was 88% (median
100%) after CDT. Grade I lysis was achieved in four pa-
Table II. Procedures and outcomes
Intervention Performed
Mechanical declot alone 12 (17%)
Thrombolytic therapy alone 27 (40%)
Thrombolytic  pulse-spray 30 (43%)
IVC filter placement 14 (20%)
Lysis grade achieved
Grade I 4 (6%)
Grade II 19 (26%)
Grade III 46 (67%)
Thrombosis recurrence 12 (17%)
Postoperative pulmonary embolism 3 (4%)
30-day survival 68 (99%)tients (6%). Grade II lysis was achieved in 19 patients(30%). Grade III lysis was achieved in 40 patients (63%)
(see Table III). For the group of 69 patients as a whole,
statistically significant clot burden reduction was achieved
in the following vessels: vena cava, iliac, common femoral,
femoral, and popliteal (see Table III).
Outcomes. Twelve patients (17%) experienced re-
thrombosis of their treated venous segments in a total of 26
lower extremity vessels (see Table III). Of the reoccur-
rences, 4 involved the vena cava, 4 involved the iliacs, 8
involved the common femoral, 5 involved the femoral, 5
involved the popliteal, and none involved the tibial-soleal.
Freedom from re-thrombosis by Kaplan-Meier analysis at
6, 12, and 24 months is 85%, 83%, and 83%, respectively
(See Fig 1). By Cox Proportional Hazard analysis, an
inherited hypercoagulable state increased the likelihood of
a patient experiencing re-thrombosis (RR 4.5, P .02),
as well as the achievement of grade I lysis (RR  6.3, P 
.02).
No peri-procedural PEs occurred. Three patients expe-
Table III. Mean clot burden reduction
Pre-CDT Post-CDT
Vena cava 0.7 0.1*
Iliac 2.2 0.2*





1  Subsegmental, nonocclusive thrombus
2  Subsegmental, occlusive thrombus
3  Occlusive thrombus, throughout length of segment
Values listed above are the mean clot burden score for each vessel, pre- and
post-CDT
*Denotes a statistically significant decrease in mean clot burden from pre- to
post-CDT.
Fig 1. Freedom from re-thrombosis. Twenty-six vessels re-
thrombosed in 12 patients (17%); 6-month, 12-month, and 24-
month freedom from re-thrombosis, by Kaplan-Meier analysis, is
85%, 83%, and 83%, respectively. Error bars are omitted for clarity.
The number of procedures at risk at each time interval is shown
below the figure. Standard error did not exceed 10% at all time
intervals that were analyzed.rienced a postprocedural PE at 33, 345, and 461 days after
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had received an IVC filter during CDT. The patients suf-
fering from PE on days 345 and 461 did not have an IVC
filter placed before, during, or after CDT therapy. Freedom
from PE at 6, 12, and 24 months is 98%, 96%, and 93%,
respectively (See Fig 2). By Kaplan-Meier analysis, no sig-
nificant difference existed for postprocedural PE formation
between patients receiving prophylactic IVC filters and
those that did not (See Fig 3). Cox Proportional Hazard
analysis found nicotine abuse (RR  107, P  .03) and
those receiving reteplase (RR  33.0, P  .005) for in-
creasing the likelihood of developing postprocedural PE.
The other pharmacologic agents, urokinase and tPA, were
not associated with an increased or decreased risk of devel-
oping postprocedure risk. Those achieving grade I lysis
(50% clot burden removal) trended towards an increase in
Fig 2. Freedom from postoperative PE. No intraoperative PEs
occurred. Three patients developed PE at day 33, 345, and 461
post-CDT; 6-month, 12-month, and 24-month freedom from PE,
by Kaplan-Meier analysis, is 98%, 96%, and 93%, respectively. Error
bars are omitted for clarity. The number of procedures at risk at
each time interval is shown below the figure. Standard error did not
exceed 10% at all time intervals that were analyzed.
Fig 3. PE prevention and IVC filter placement. 20% of the pa-
tients received prophylactic IVC filter placement. No difference
existed, by Kaplan-Meier analysis, in freedom from postoperative
PE between patients with IVC filter placement and those without
IVC filter placement. Error bars are omitted for clarity. The
number of procedures at risk at each time interval is shown below
the figure. Standard error did not exceed 10% at all time intervals
that were analyzed.postprocedure PE with a relative risk of 12.7, but wasstatistically insignificant (P  .11). All other factors were
insignificant.
Patients were followed for a mean 2.1 years (median
1.5 years). One death occurred within 30 days and 11
deaths occurred within 1 year (see Table II). The propor-
tion of patients surviving by Kaplan-Meier analysis at 6, 12,
and 24 months is 84%, 82%, and 72%, respectively.
DISCUSSION
We found CDT extremely effective at reducing clot
burden with 94% of our patients achieving greater than
or equal to 50% clot burden reduction. The individual
reduction in limb score for all 69 patients is shown in Fig
4. Patients receiving stents were at an equivalent risk for
re-thrombosis (P  .18) and PE (P  .77) when com-
pared to non-stented patients by 2 analysis. We did not
observe the choice of thrombolytic agent used during
CDT resulting in a greater or lesser reduction in clot
burden vs the other thrombolytic drugs, which corre-
sponds with what others have found.10 However, we did
observe a significant increase in risk (RR 33, P .005)
for postoperative occurrence of PE in patients treated
with reteplase. Two of the three patients that developed
postprocedural PE had received reteplase during CDT.
However, the patients receiving reteplase had a higher
rate of nicotine abuse, which was found by Cox Propor-
tional Hazards analysis as a significant risk factor for PE
formation, (80%) vs the group overall (41%). Whether
reteplase is a significant risk factor for post-CDT PE
formation or whether the risk is just an association to
these patients also having increased rates of nicotine
abuse, we cannot definitively comment upon.
Currently, IVC filter placement is provider specific with
no departmental guidelines.While we do not perform univer-
sal prophylactic IVC filter placement, we do recommend
prophylactic IVC filter placement for patients with free float-
ing IVC thrombus. In retrospect, we did not find patients
with a more extensive clot involving the vena cava receiving
filters at a significantly greater rate. Patients with an identifi-
able hypercoagulable state were receiving filters at a greater
rate, 38% vs 13% (P  .01). OCP usage did not increase or
decrease the likelihood of re-thrombosis or PE development.
Since it is protocol to stopOCPusage and opt for other forms
of birth control, we assume that the re-thrombosis risk returns
Fig 4. Limb score for all 69 patients. Clot burden pre- and
post-CDT.to baseline after cessation of OCPs.
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of 69 interventions (4%), and no deaths occurred intra-oper-
atively.Most of the deaths occurred outside of our institution.
During the entire length of follow-up, 18 patients expired.
Only four of them occurred at our institution. The remaining
deaths were discovered by querying the Social Security Death
Index. Thus, we are confident which patients expired, but not
as to the cause for themajority of them.With only one patient
(1%) greater than 80 years of age and six patients (9%) greater
than 70 years of age, our 6-month survival of 84%  5% by
Kaplan-Meier analysis appears low. We did not have any
patients expire due to a massive pulmonary embolism or
peri-procedural complications, and thus, would expect our
6-month survival rate to be higher. Perhaps the nine patients
(13%) with a current malignancy is accounting for the lower
than expected 6-month survival rate. The patient, who ex-
pired within 30 days, was a 60-year-old gentleman with long-
standing liver failure, who died due to poly-microbial sepsis
and ARDS. At the time of CDT he was 5 weeks status-post
liver transplant.
Our freedom from re-thrombosis, 83%  5% at one
year follow-up, is comparable to other current re-
ports.9,11-14 Our median time to re-thrombosis was 87 days
post-CDT. Thus, a large proportion of our patients with
thrombosis recurrence are occurring far after CDT, and are
most likely re-thrombosing due to an inherited hypercoag-
ulable state (RR  4.5) or due to an anatomical defect
predisposing them to thrombosis.
This study spans a course of 10 years in which some of
the hypercoagulability tests (eg, factor V Leiden and pro-
thrombin gene mutations) were unavailable. Not all of the
69 patients were worked up for genetic predispositions
towards a hypercoagulability. Thirty and 29 patients were
worked up for protein C & S deficiency, respectively.
Twenty and 19 patients were evaluated for factor V Leiden
and prothrombin gene mutations, while 25 were evaluated
for lupus anticoagulant. Currently, all patients without a
known current malignancy receive a complete thrombo-
philia workup.
A recent meta-analysis15 demonstrated the relationship
of clot burden reduction and likelihood of recurrent
thromboembolism. We found similar results with three out
of four patients with grade I lysis would later develop new
thrombosis. Four out of 19 achieving grade II lysis and five
out of 40 achieving grade III lysis would develop re-
thrombosis during follow-up.
We found nicotine abuse and reteplase usage to corre-
late with PE development post-CDT. The three patients
developing postoperative PE each had different lysis grades
(ie, one patient had grade I, one had grade II, and one had
grade III) after completion of CDT, and as mentioned
above, IVC filter placement did not show a significant
reduction in post-CDT PE formation. As mentioned in the
Results section, the patients with 50% clot burden re-
moval at the end of CDT had an insignificant (P  .11)
relative risk of 12.7 for post-CDT PE formation. We are
unaware of any previous reports indicating reteplase usage
for clot lysis as an independent risk factor for PE formation.We are aware of nicotine abuse as a risk factor for PE
formation in women,18 while others have reported no
association.19,20 The retrospective design limits our study.
Our sample size, while small is one of the largest in the
literature. An important note, as described in the Methods
section, is that we do not routinely screen for PEs. We do
not go looking for PEs without sufficient clinical suspicion.
Patients with and without IVC filters may well have devel-
oped clinically silent PEs. Partsch et al16 followed 140
consecutive patients with confirmedDVT. At initial presen-
tation all of the patients underwent V/Q scanning, and
46.4% were found to have verified PE. Meanwhile, only
13.6% of their patients demonstrated symptomatic PE. We
recognize that for every one patient presenting with a
confirmed DVT and symptoms consistent with PE there
are roughly three and a half patients with a confirmed DVT
and a clinically-silent PE. Thus, since we do not routinely
scan for PEs, we cannot draw conclusions on the effective-
ness or ineffectiveness of IVC filter placement for clinically
silent and clinically significant PE formation post-CDT, but
rather just for clinically significant PE formation.
While IVC filter placement was provider specific with
no departmental guidelines, we recognize that the patients
receiving IVC filters in our study likely represent patients at
highest risk for post-CDT PE formation. Thus, there is a
potential selection bias, which limits our study; however
others17 have also reported low PE formation during CDT.
Further prospective studies are necessary for definitive an-
swers regarding the effectiveness of IVC filter placement
during CDT.
CONCLUSION
Catheter directed thrombolysis without universal pro-
phylactic IVC filter placement is safe and effective in treat-
ing acute DVT. Pulmonary embolization did not occur
during CDT. Selective rather than routine IVC filter place-
ment is a safe and appropriate approach.
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DrCynthia K. Shortell (Durham, NC). The appropriate use of
IVC filters during venous lysis has not been previously addressed in a
systematic fashion. The questions, as I see it, are: Should everyone get
a filter? Should no one get a filter? Or should some people get a filter?
And if so, what determines that -- clot burden, hypercoagulable state,
prior history of pulmonary embolism, use of mechanical thrombec-
tomy devices, or something else?
To this end, I have the following questions for the authors. In
the Methods section of the manuscript, the authors state that the
decision to place an IVC filter was “provider specific.” In the
Procedures section, it stated that IVC filters were placed in 16% of
patients, or 11 patients, and that in addition, three patients had
existing IVC filters. So that, in total, 21% of patients included in the
analysis were actually protected by IVC filters.
Since the manuscript that I received, you have addressed this
issue partially in the slides that you presented today. But consider
this, additionally as the indications for filter placement are vague, is
it possible that the patients at highest risk for pulmonary embolism,
either because of past history of PE or because of intercurrent risk
factors, had filters in place for the procedure?
The authors do not comment on the role of optional filters or
retrievable filters in this setting. Has their attitude toward filter place-
ment changed since the introduction of these devices? How many of
the filters placed were retrievable and how many were retrieved?
What were the clinical features of the patients who had late
PE? Were they life-threatening events? Given that three patients
had late PEs, a high percentage in a small study, and that PE results
from recurrent DVT, would the authors consider recommending a
selective policy of permanent filters in these patients?
The authors note that only three complications occurred,
none of them related to IVC filter, in the 14 patients who had
them, including the 11 fresh filters. The authors also alternatively
could conclude that IVC filter use is safe in the setting of throm-
bolysis for DVT. Do the results presented really support the
conclusion of the abstract, namely, that CDT for DVT is safe and
effective, and that IVC filter is not required, presumably, ever?
Given the relatively low complication rate of IVC filters,of PE even if rare, how do the authors justify their absolute
commitment to this conservative approach?
Dr Clinton D. Protack. Thank you Dr Shortell for reviewing
the manuscript and for your kind comments and questions. Ad-
dressing your three main questions we believe: (1) not everyone
should receive an IVC filter, (2) IVC filters provide a treatment
role in certain patients, (3) patients with prior PE, patients with
free-floating thrombus at the end of CDT, and those patients with
IVC thrombus would benefit from IVC filter placement.
I would agree that those with pre-existing filters had been
deemed high risk before we saw them. As we did a retrospective
study, we can only go with provider specific placement.We have no
unit guidelines and we do not systematically place IVC filters
before therapy. Given this environment, we would conclude that
based on the clinical judgment of the provider at the time of
procedure the patients were at high risk of a PE.
With regards to retrievable IVC filters, two of the 11 filters
placed were retrievable. The study spans a decade in which there
were no retrievable filters to the present where there are several.
Looking at the last 3 years we have only placed retrievable IVC
filters in clots that extended into the IVC. We have not seen a
major shift to placement just because we can retrieve them.
The study, while one of the largest in the current literature, is
perhaps too small to address a policy of permanent IVC filters in
high risk patients. At present, these three failures occurred on
anticoagulation. They, thus, met the criteria of failure of anticoag-
ulation, and we would place permanent filters. We would go with
the guidelines in these situations.
I think that is not an unreasonable argument that IVC filter
use is safe in the setting of thrombolysis for DVT. Following, I
would say that using a selective rather than a universal policy is
safer. However, following the same thinking, we also found no
benefit for filter placement. So while they do no harm, they provide
no benefit, and add a financial cost.
If we look at the success of CDT, it is excellent with a low
morbidity. In our hands, we did not suffer significant problems
because we did not routinely place a filter. We would agree that in
the right setting and the appropriate patient, IVC filter placement
remains a safe procedure. The enemy of good can often be better.
